Seven Eight Capital, LP Biogen Inc. Transaction History

Seven Eight Capital, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$212.02 - $267.71 $365,522 - $461,532	1,724 New	1,724 $371,000
Q2 2021 Aug 13, 2021	SELL	$259.0 - $414.71 $973,840 - $1.56 Million	-3,760 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$236.26 - $355.63 $888,337 - $1.34 Million	3,760 New	3,760 $921,000
Q1 2020 May 14, 2020	SELL	$268.85 - $341.04 $2.51 Million - $3.18 Million	-9,326 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$220.06 - $304.07 $7.04 Million - $9.73 Million	-32,000 Reduced 77.43%	9,326 $2.77 Million
Q3 2019 Nov 14, 2019	SELL	$217.44 - $243.88 $6.89 Million - $7.72 Million	-31,674 Reduced 43.39%	41,326 $9.62 Million
Q2 2019 Aug 12, 2019	BUY	$219.29 - $241.72 $16 Million - $17.6 Million	73,000 New	73,000 $17.1 Million
Q2 2018 Aug 07, 2018	SELL	$257.52 - $306.91 $721,056 - $859,348	-2,800 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$260.13 - $367.91 $728,364 - $1.03 Million	2,800 New	2,800 $767,000
Q3 2017 Oct 16, 2017	SELL	$281.15 - $329.69 $1.38 Million - $1.62 Million	-4,900 Closed	0 $0
Q2 2017 Aug 10, 2017	BUY	N/A	4,900	4,900 $1.33 Million

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.